THE FIRST AND ONLY PSMA-targeted radioligand therapy for men with PSMA+ mCRPC who have been treated with androgen receptor pathway inhibitors and taxane-based chemotherapy.
Based on in vitro/in vivo studies. Preclinical activity does not correlate with clinical outcomes.
mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.
About PLUVICTO
DNA, deoxyribonucleic acid.
PLUVICTO targets PSMA-positive cells including prostate cancer cells1
PLUVICTO is comprised of 2 key components: Lutetium-177, a cytotoxic radionuclide, and PSMA-617, a PSMA-targeting ligand.1
PLUVICTO binds with high affinity to PSMA, a transmembrane protein overexpressed on prostate cancer cells.1 After binding to PSMA, PLUVICTO undergoes endocytosis and is internalized into the cell.1-4
Lutetium-177, the cytotoxic radionuclide of PLUVICTO, emits DNA-breaking radiation within the cell. The short path length of the radiation emitted by PLUVICTO, approximately 2 millimeters maximum,1 causes single- and double-stranded DNA breaks in the targeted cells as well as surrounding cells, which can lead to cell death.1,4-6
Scanning to confirm PSMA+ mCRPC is key to identifying patients who may benefit from PLUVICTO.1
CT, computed tomography; PET, positron emission tomography.
Manufacturing PLUVICTO
Learn how PLUVICTO gets to patients
Watch the manufacturing video to explore how PLUVICTO gets from production to patients.
Discover where your patients can receive treatment with PLUVICTO